Genmab (NASDAQ: GMAB) Just Broke Out on a MASSIVE Cancer Drug Win — Could Soar 31%

Genmab A/S (NASDAQ: GMAB) just broke out of a four-month uptrend channel to a three-year high on a +10.7% single-session surge — and looks headed even higher.

As we’ll get to just ahead, the combination of a landmark trial win that could move its fast-growing blood-cancer drug into a much larger market, strong new results from a second cancer drug it fully owns, and a fresh technical breakout makes GMAB one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

Genmab is a Copenhagen-based biotech that develops antibody-based medicines for cancer and other serious diseases. It co-markets EPKINLY (epcoritamab) with AbbVie for certain lymphomas, sells Tivdak for advanced cervical cancer, and collects royalties on partner-sold drugs — most importantly Johnson & Johnson’s multiple myeloma blockbuster DARZALEX, along with Kesimpta, TEPEZZA, and others. Its late-stage pipeline includes Rina-S for ovarian cancer and petosemtamab, which it gained through its roughly $8 billion acquisition of Merus.

In plain English, Genmab makes money two ways: it collects a large, steady stream of royalty checks from blockbuster drugs that big pharma partners sell, and it increasingly sells cancer drugs of its own. That royalty engine pays for a deep pipeline — and when one of those pipeline drugs wins a major trial, it can reshape the company’s long-term earnings power.

GMAB’s latest move reflects a powerful confluence of developments — clinical, commercial, and financial — that have come together in rapid succession to fundamentally reframe the company’s growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and GMAB is looking less like a royalty collector leaning on one partner’s blockbuster and more like a profitable, self-funding oncology company with multiple growth engines firing at once — two Phase 3 lymphoma wins this year, a wholly owned ovarian cancer drug delivering strong data, and two more major readouts on deck before year-end.

The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Uptrend Channel Breakout: Since its June low near $23.60, GMAB has climbed steadily inside a rising channel, marked in purple on the daily chart, adding roughly 60% while respecting both rails. Yesterday the stock broke out of the top of that structure, jumping +10.73% to close at $38.48 and clearing the upper rail with room to spare. Because this channel was already rising, the breakout doesn’t reverse the trend. It speeds it up: demand is now outrunning the channel’s own slope. The move also cleared the $36.00 horizontal ceiling that capped every rally through September, so two layers of resistance gave way in one session. Volume reached 12.4 million shares, the largest bar on the chart by a wide margin, which shows institutional sponsorship rather than a drift through thin air. The timing is notable too: only one session earlier, price had tagged the channel’s lower rail near $33.80, so buyers carried the stock from floor to ceiling and beyond in two sessions. One caveat is that the session high of $40.17 faded into the close, leaving an upper wick right at the $39.60 trigger. Sellers showed up there, and a clean push through that level is what turns the breakout into a confirmed leg higher.

GMAB – Daily Chart

#2 Price Above 50-Day and 200-Day SMAs: GMAB trades well above both its 50-day SMA ($32.86) and 200-day SMA ($29.66). The 50-day crossed above the 200-day in August, and that golden-cross alignment has only widened since. The 50-day is rising steeply while the 200-day has turned up as well, so short-term and long-term trend direction agree. Together with the breakout, these averages form tiered support: first the old $36.00 ceiling and the upper channel rail just above it, then the 50-day near $33, then the 200-day near $29.70. Tiered support matters because a failed breakout would still have several places to stabilize before the broader uptrend came into question. The honest tension is extension. After yesterday’s surge, price sits about 17% above the 50-day and nearly 30% above the 200-day, so a pullback toward $36.00 would be a normal retest of broken resistance. It would not break the thesis, which is why the pullback entry offers the better-quality risk profile.

#3 Bullish ADX and DI: Both parts of the ADX reading favor the bulls. On direction, +DI (49.08) has spiked far above –DI (16.43), a nearly 3-to-1 margin that shows buyers firmly in control of price movement. On strength, ADX (31.47) has turned sharply higher from a reset near 20 in late September, moving decisively through the 25 threshold that separates a trending market from a range-bound one. The reset is the useful detail. ADX peaked near 40 during the August rally, cooled during the September consolidation, and is now re-accelerating, so a fresh impulse is starting rather than an old trend running out of steam. With ADX climbing between the two DI lines, still well below +DI, trend strength has room to build before it reaches the extreme readings that tend to come before exhaustion.

#4 Bullish Aroon: The Aroon indicator shows the strongest reading it can produce: Aroon Up at 100% and Aroon Down at 0%. An Aroon Up of 100 means GMAB printed a new 14-period high in the latest session, which matches the channel breakout. An Aroon Down of zero means no new 14-period low has appeared in the entire lookback window. The persistence is just as telling as the extreme. Aroon Up has stayed in the 80–100 band since mid-September, so new highs have kept coming rather than arriving in one isolated burst. When one line is pinned at the top and the other is flat on the floor, the trend is established and one-sided, with buyers setting the pace and sellers unable to force fresh lows.

#5 Above Support Area with Price Above 50-Week and 200-Week SMAs: On the weekly chart, GMAB has pushed clear of a well-defined support area near $34.35 (pink dotted line). That zone capped the stock’s late-2025 rallies before price broke above it in September. Last week’s dip toward the zone was bought and reversed, which is the behavior of a level that has truly flipped from resistance to support. The moving-average picture adds a fresh development: the 50-week SMA ($29.93) has just edged above the 200-week SMA ($29.60). That weekly golden cross is the first since the 2023–2024 downtrend took hold, and the narrow $0.33 gap shows how recent it is. It marks a structural shift in GMAB’s long-term trend, not just a short-term bounce. Price now trades near the levels where the stock broke down in late 2023, so the $39.60 trigger is effectively a gateway back into that former trading range. When daily and weekly structure agree like this, with a daily channel breakout above a weekly flipped support zone and a new long-term golden cross, the signal carries more weight than either timeframe could alone.

GMAB – Weekly Chart

#6 Bullish MACD: The weekly MACD line (2.16) is above its signal line (1.37), and the histogram (0.78) is positive and widening. The crossover itself happened near the zero line in mid-2026, which is the highest-quality form of the signal. A crossover there means momentum turned positive from a neutral base rather than snapping back from an oversold extreme. Since then, both lines have climbed well above zero, confirming that momentum has moved from early recovery into an established uptrend. The widening histogram matters most here: the gap between short-term and long-term momentum is still growing, so the trend is gaining speed rather than leveling off. Read alongside the daily ADX re-acceleration, the two timeframes agree that the latest push has fresh energy behind it.

#7 Bullish RSI: The weekly RSI has followed a classic two-step path. It first reclaimed the 50 midline around mid-2026, handing momentum control to buyers. It has since kept rising, a sign that momentum is expanding rather than stalling. It now reads 75.65, about ten points above its signal line (65.05), so the short-term pace of buying is outrunning its own recent average. The honest caveat is that RSI has moved into overbought territory above 70. Overbought readings are common in strong trends and can last for weeks, so this is not a sell signal. Still, the last time weekly RSI ran this hot, in October 2025, a multi-week cooling-off followed. Strong momentum plus a stretched oscillator is exactly the setup in which the $36.00 pullback entry earns its place alongside the breakout entry.

Risks to Consider

Even strong setups can fail, especially in a catalyst-driven biotech like Genmab. A few things could knock the stock off course:

• A breakdown back inside the uptrend channel — and below the $36.00 breakout level — on heavy volume would invalidate the breakout thesis
• Negative company-specific news, broader market weakness, or regulatory changes across the biotech sector could trigger a sell-off
• Short-term extension risk — GMAB closed at $38.48 (+10.73%) on October 5, and the Copenhagen-listed shares rose roughly another 7.6% on October 6, raising the risk of chasing a stretched move
• Clinical and regulatory risk for EPKINLY — not every Phase 3 has been clean; the EPCORE DLBCL-1 monotherapy study failed to show a statistically significant overall survival benefit, and full DLBCL-2 data and regulatory reviews are still ahead
• Q4 binary events — the Phase 3 Rina-S and frontline petosemtamab readouts could move the stock sharply either way, and strong Phase 2 data can’t guarantee Phase 3 success
• Competition — rival ADCs in ovarian cancer and other bispecific antibodies in lymphoma and head and neck cancer, including Roche’s glofitamab, could limit market share
• Debt load from the Merus deal — Genmab carried $5.135 billion in borrowings against $1.503 billion in cash at June 30, and higher financing costs helped cut H1 net profit to $356 million from $531 million a year earlier
• Royalty concentration and litigation — DARZALEX royalties (about $2.83 billion expected this year at guidance midpoint) still drive much of the business, and AbbVie is suing over alleged trade-secret misappropriation tied to Rina-S (Genmab contests the claims and has recorded no provision)

The Bottom Line

GMAB is breaking out of a four-month uptrend channel on the daily chart while holding above a resistance-turned-support zone with a fresh golden cross on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: a landmark Phase 3 win in frontline lymphoma, strong ovarian cancer data from its wholly owned Rina-S, and 25% first-half revenue growth with raised FY26 guidance.

Combine that with multiple clinical and commercial catalysts staggered through Q4 2026 and into 2027 — the Phase 3 Rina-S readout, the frontline petosemtamab Phase 3 topline, Q3 results on November 5, and potential 2027 launches — and GMAB looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our two entry options, both price targets that imply 19%–31% potential upside on a breakout entry (or 31%–44% on a pullback entry), and the stop-losses we’re using to manage the downside.

Recommended Trade Setup

We’re offering two ways to play this setup. The breakout entry gets you in as soon as GMAB pushes cleanly through the $39.60 trigger where sellers showed up yesterday. The pullback entry waits for a retest of the broken $36.00 ceiling — a better risk-reward profile given how stretched the stock is in the short term.

Case 1: On Breakout

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $4.10 per share, the target rewards are about $7.40 and $12.40 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If GMAB drops to or below the $35.50 stop-loss before the $39.60 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Case 2: On Pullback

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $5.50 per share, the target rewards are about $11.00 and $16.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Happy Trading!
Tara and Greg